Why the data on LMIC and EU patient access both point to the same conclusion: the pharmaceutical commercialization playbook needs to be rewritten before leadership of the industry shifts East
1. The LMIC access gap: years, not months
A 2024 Health Affairs analysis of IQVIA launch data spanning 1982–2024, covering 119 essential medicines and nearly 6,900 country-level launches across 75 markets, put a hard number on something the industry has long sensed qualitatively: newly available medicines reach different income tiers at radically different speeds. Measured from the date of first global launch, the median time to availability was 2.7 years in high-income countries, 4.5 years in upper-middle-income countries, 6.9 years in lower-middle-income countries, and 8.0 years in low-income countries. Nearly three-quarters of all first launches — 74% — occurred in just eight countries: the US, the Netherlands, Sweden, Switzerland, the UK, France, Germany, and Japan.
A separate 2025 IQVIA study, commissioned by IFPMA across 18 LMICs, sharpens the picture for recently launched medicines. Of 593 medicines first launched globally between 2013 and 2022, only 31 — about 5% — have made it onto the WHO Essential Medicines List, and coverage across national registries, reimbursement lists, and global procurement mechanisms remains thin and inconsistent. IQVIA’s Global Use of Medicines 2025 report adds the demand-side counterpart: lower-income countries receive fewer than half of all novel drugs, per-capita medicine use is five- to six-fold higher in high-income countries than in Africa, the Middle East, and large parts of Asia and Latin America, and volume growth in low-income countries is forecast at a fraction of the rate seen in wealthier “pharmerging” markets.
This is the classic access argument, and it is usually filed under patient equity or corporate social responsibility. The data from Europe suggests it should be filed under something else: business model design.
2. The EU access gap: the same failure, in the world’s second-largest market
EFPIA’s Patients W.A.I.T. Indicator — the longest-running, most granular tracker of medicine access in Europe — shows that the sequential, country-by-country commercialization model is failing even inside one of the pharmaceutical industry’s home markets. The 2025 survey (covering 173 centrally approved medicines, data current to January 2026) found the EU average time from marketing authorisation to patient access reached 597 days, up from 578 the year before and 526 four years earlier — the gap is widening, not closing. Only 28% of medicines were fully available through public reimbursement, down from 42% in 2019, while 17% were available only under restriction, up from 6%.
The country-level spread is the more damning number for anyone still describing “Europe” as a single market: patients in Germany wait roughly two months for a new medicine; patients in Romania, Portugal, or Poland can wait two to three-and-a-half years for the identical product — an 88% access disparity between the fastest and slowest EU member states, or roughly a seven-fold difference. A companion EFPIA root-cause study found the majority of that delay (about 69%) sits in the post-filing reimbursement decision, not the regulatory approval step, meaning it is a commercial and market-access design failure rather than a science or safety bottleneck.
Two other numbers from the same body of research matter for the argument that follows: the US now accounts for roughly 74% of global sales of newly launched active substances, versus about 16% for Europe — and EFPIA itself now flags that if current approval trends persist, China is on track to overtake the EU in the number of FDA-approved medicines it subsequently approves and launches domestically.
3. Reading the two datasets together
Put the LMIC and EU numbers side by side and a pattern emerges that neither dataset shows on its own:
| LMIC (2024 launch cohort study) | EU27 (2025 W.A.I.T. survey) | |
|---|---|---|
| Median/average time to access | 6.9–8.0 years (LMIC/LIC) | ~1.5–1.6 years (597 days) |
| Best-performing tier | High-income: 2.7 years | Germany: ~4 months |
| Worst-performing tier | Low-income: 8.0 years | Portugal/Romania: 2.3–3.3 years |
| Share of medicines that reach the market at all | ~5% of recent launches on WHO EML in sampled LMICs | 28% fully reimbursed, 49% unavailable |
The magnitudes differ by an order of magnitude, but the mechanism is identical: a launch sequence still architected around eight anchor countries, followed by a slow, discretionary cascade of national filing, pricing, and reimbursement decisions everywhere else — rich European member state or low-income market alike. The current playbook does not fail LMICs because they are poor; it fails everyone downstream of the first eight launch countries, and it fails them proportionally to how far outside that cluster they sit, whether that distance is measured in GDP per capita or in the size of a national HTA queue.
4. Why this is a business case, not only a patient-access case
a. The growth math no longer favours a West-first sequence.
Pharmerging markets are projected to grow from roughly $1.79 trillion (2023) to $4.13 trillion by 2033 — an 8.7% CAGR that outpaces developed-market growth by a wide margin. Developed markets’ share of global pharmaceutical spend is projected to fall from about 69% in 2022 to 63% by 2027, with emerging markets’ share rising from 31% to 37% over the same window. A commercialization model that reaches its highest-growth markets years after its slowest-growth ones is, by construction, mistiming its own revenue curve.
b. Real-world evidence is becoming a competitive asset, and it is being generated where the patients are.
China’s share of global commercial clinical trials has doubled since 2018; Chinese-origin assets accounted for roughly 40% of global licensing deals in 2025, up from just 3% in 2020; and China now contributes an estimated 23% of new drugs entering the global pipeline, second only to the US. As payers and regulators everywhere lean harder on real-world data for pricing, reimbursement, and label expansion decisions, a company that only generates RWE in eight early-launch countries is building an evidence base that under-represents the populations — and disease profiles — that will define the next decade’s growth.
c. Delay is now a shared cost, not a developed-market shield.
The EU data shows that “launch late in the West too” is not a safe fallback position — it produces the same access failure, litigated the same way in the press, parliaments, and patient-advocacy campaigns that LMIC access failures have been litigated for two decades. EFPIA is already campaigning publicly on this exact point.
5. The leadership shift is a five-year problem, not a fifty-year one
None of the above requires speculation about disruption. It is visible in the growth curves already in hand: pharmerging markets compounding at nearly 9% against a mature-market base growing at low single digits; China’s medicine-use index tracking toward 196 (versus a 2020 baseline of 100) by 2030; and an innovation pipeline where a Western-originated, Western-first launch sequence increasingly under-represents where both the growth and the intellectual property are coming from. On the current trajectory, the commercial and scientific center of gravity in pharmaceuticals plausibly relocates East within roughly half a decade — not because Western markets shrink in absolute terms, but because the growth, the trial capacity, and increasingly the originating molecules do not sit there anymore.
6. The rewrite: what the playbook needs to do differently
The case here is not “do more access programs.” It is a structural proposal:
1. Replace sequential launch with tiered-parallel launch — design the eight-anchor-country wave and the next 40–60 markets (EU periphery, MENA, Sub-Saharan Africa, CIS, Southeast Asia, Latin America) as concurrent regulatory and access workstreams, not a waterfall.
2. Treat technology transfer and regional manufacturing partnerships as launch infrastructure, not an afterthought monetized after patent expiry — this is the only way to close an 8-year gap, not a 1.5-year one, in the lowest-income tier.
3. Build RWD collection into early-market access agreements in emerging markets, converting an access concession into a data asset that strengthens the global evidence package.
4. Use equity-based or tiered pricing and outcomes-based reimbursement — tools EFPIA itself is now proposing for the EU periphery — as the standard access mechanism for both LMICs and lagging EU states, rather than two separate policies for two problems that the data shows are one problem.
The industry has spent two decades treating LMIC access as a philanthropic obligation and EU access delay as a regulatory nuisance. The data says they are the same failure mode, and the growth curves say the market least tolerant of that failure mode much longer is the one currently being kept waiting longest.
Sources: Health Affairs (Oct 2024, IQVIA launch data 1982–2024); IFPMA/IQVIA “Key Access Pathways and Bottlenecks for Medicines in LMICs” (2025); IQVIA Institute, “The Global Use of Medicines 2025: Outlook to 2029”; IQVIA Institute, “Global Medicine Use Trends 2026”; EFPIA Patients W.A.I.T. Indicator, 2024 and 2025 Surveys; EFPIA/CRA “The Root Causes of Unavailability of Innovative Medicines and Delay in Access” (2025); EFPIA/CRA “European Access Hurdles Portal” (2025); Euronews reporting on the 2026 W.A.I.T. release; DrugPatentWatch pharmerging market analysis; Evaluate World Preview 2030; Drug Discovery World on China’s biopharma trajectory.
The Author is Chief Operating Officer, Meraki Life Sciences (SMC-Pvt) Limited. He can be reached at sohailmanzoor@merakils.org